The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 15, 2015

Filed:

Sep. 14, 2010
Applicants:

Dae-yoon Chi, Seoul, KR;

Byoung-se Lee, Seoul, KR;

Sirion Uthaiwan, Chainat, TH;

So-young Chu, Seoul, KR;

Yu-jin Bae, Incheon, KR;

Chansoo Park, Seoul, KR;

Dae-hyuk Moon, Seoul, KR;

Jin-sook Ryu, Seoul, KR;

Jae-seung Kim, Seoul, KR;

Seung-jun OH, Seoul, KR;

Inventors:

Dae-Yoon Chi, Seoul, KR;

Byoung-Se Lee, Seoul, KR;

Sirion Uthaiwan, Chainat, TH;

So-Young Chu, Seoul, KR;

Yu-Jin Bae, Incheon, KR;

Chansoo Park, Seoul, KR;

Dae-Hyuk Moon, Seoul, KR;

Jin-Sook Ryu, Seoul, KR;

Jae-Seung Kim, Seoul, KR;

Seung-Jun Oh, Seoul, KR;

Assignee:

FUTURECHEM CO., LTD., Incheon, KR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 417/04 (2006.01); A61K 31/4436 (2006.01); C07D 277/66 (2006.01); C07D 409/04 (2006.01); C07D 471/04 (2006.01);
U.S. Cl.
CPC ...
C07D 277/66 (2013.01); C07D 409/04 (2013.01); C07D 417/04 (2013.01); C07D 471/04 (2013.01);
Abstract

The present invention relates to (3-fluoro-2-hydroxy)propyl-functionalized aryl derivatives or to the pharmaceutically acceptable salt thereof, to a method for preparing same, and to a pharmaceutical composition containing same as active ingredients for the diagnosis or treatment of neurodegenerative brain diseases. The aryl derivatives of the present invention are (3-fluoro-2-hydroxy)propyl-functionalized to increase the polarity thereof, and therefore the drugs containing the aryl derivatives can easily permeate into the cerebrovascular membrane, thus increasing the effectiveness of the drugs. As the aryl derivatives of the present invention strongly bind to β-amyloid, the aryl derivatives, when labeled with radioisotope, can be used as a diagnostic agent for non-invasively diagnosing early Alzheimer's disease. Further, the aryl derivatives of the present invention bind to low molecular β-amyloid peptide conjugates to inhibit the generation of malignant high molecular β-amyloid plaque, and thus can be effectively used as a therapeutic agent for neurodegenerative brain diseases such as Alzheimer's disease.


Find Patent Forward Citations

Loading…